Cargando…
Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074807/ https://www.ncbi.nlm.nih.gov/pubmed/30104886 http://dx.doi.org/10.2147/OTT.S179985 |
Ejemplares similares
-
Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018) -
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis
por: Zhang, Jingwen, et al.
Publicado: (2017) -
Corrigendum to “Network meta-analysis of immune-oncology monotherapy as
first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1
expression ⩾50%”
Publicado: (2022) -
Corrigendum to “Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis”
por: Liu, Weiping, et al.
Publicado: (2021) -
Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)